期刊
JOURNAL OF NEUROIMMUNOLOGY
卷 356, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.jneuroim.2021.577583
关键词
Experimental autoimmune encephalomyelitis; Multiple sclerosis; Ponesimod; Sphingosine-1-phosphate receptor; Th1; Th17; Treg
资金
- National Natural Science Foundation of China [81701186]
- key project of Medical Science Research in Hebei Province [20200868]
Ponesimod treatment improved EAE and reduced inflammatory infiltration, decreasing Th1 and Th17 cell numbers while increasing Treg cell numbers, and modulated the levels of related cytokines and signaling pathways.
Sphingosine-1-phosphate receptor 1 (S1P1) plays an important role in autoimmune disease. Here, we evaluated whether ponesimod, an S1P1 modulator, affects inflammation in experimental autoimmune encephalomyelitis (EAE) and investigated Th1/Th2/Th17/Treg cell subsets. Ponesimod treatment ameliorated EAE and alleviated inflammatory infiltration. Compared with untreated EAE, ponesimod-treated mice had lower Th1 and Th17 cell numbers and higher Treg cell numbers; their IFN-gamma, T-bet, IL-17, and ROR gamma t levels as well as their pmTOR/mTOR ratio were diminished, while their TGF-beta and Foxp3 levels were enhanced. These results suggest that ponesimod modulates the Th1/Th17/Treg balance and regulates the mTOR pathway.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据